Back to search results
NCT07508228

A Study to Understand How a Study Medicine Called PF-07328948 is Absorbed and Processed in the Body of Healthy Male Adults

Completed
PHASE1Ages 18–64InterventionalBasic science
Pfizer
~8 participants
Updated 2026-08-06 on ClinicalTrials.gov
What's tested:Oral [14C]PF-07328948Oral Unlabeled PF-07328948IV [14C]PF-07328948

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Total recovery of radioactivity in urine, feces, expired air (if analyzed and if reportable), and emesis (if any), and all routes combined, expressed as a percentage of oral radioactive dose administered.
Measured over Period 1 pre-dose to maximum Days 22

Conditions

Healthy

Explore related trials

Healthy

Where it's being run

1 sites across 1 states
Wisconsin1

Study leadership

  • Pfizer CT.gov Call Center · STUDY_DIRECTOR · Pfizer

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male participants aged ≥18 years to \<65 years at screening who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and ECGs.
BMI of 17.5-32 kg/m2; and a total body weight \>50 kg (110 lb).

Exclusion

Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease.
Previous administration of an investigational product (drug or vaccine) within 30 days or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer). Participation in studies of other investigational products (drug or vaccine) at any time during participation in this study.
Background radioactivity measured in plasma and/or urine at screening exceeding an F14C value of 2.5.
Prior participation in a radiolabeled ADME clinical study within 12 months prior to screening.

What this trial measures

  • Total recovery of radioactivity in urine, feces, expired air (if analyzed and if reportable), and emesis (if any), and all routes combined, expressed as a percentage of oral radioactive dose administered.Period 1 pre-dose to maximum Days 22